Trigen Holdings AG Appoints Dr. Ayad Abdul-Ahad as Chief Executive Officer and Dr. Norbert Bender as Chief Medical Officer
7/23/2008 1:17:26 PM
More...
|
Trigen Holdings AG's Innovative Platelet Adhesion Inhibitor, PR-15, Successfully Completes First-in-Man Phase I Study
5/1/2007 11:16:22 AM
More...
|
Trigen Holdings AG Opens IND For The Initiation Of A Phase III Programme For Flovagatran (Formerly TGN 255), Its Novel Intravenous Direct Thrombin Inhibitor (DTI)
2/6/2007 10:34:20 AM
More...
|
Trigen Holdings AG Obtains Exclusive License To GPVI Technology
1/23/2007 10:31:40 AM
More...
|
Trigen Holdings AG Initiates Clinical Development With A Novel Therapeutic Protein, targeting Thrombosis And The Progression Of Atherosclerosis
12/13/2006 11:32:49 AM
More...
|
Trigen Holdings AG Strengthens Its Supervisory Board With The Appointment Of Grahame Cook As A Non-Executive Director
9/27/2006 10:41:41 AM
More...
|
Trigen Holdings AG Presents Phase II Results For Its Intravenous Direct Thrombin Inhibitor, TGN 255, For The Prevention Of Clotting During Hemodialysis
7/17/2006 12:05:35 PM
More...
|
Trigen Completes €26.5 Million Financing Round
10/19/2005 5:13:20 PM
More...
|
Eurand (Milan, Italy) And Trigen Ltd. Announce A Development Collaboration For Trigen's Novel Oral Anticoagulant, TGN 167
10/19/2005 5:12:17 PM
More...
|